NGM Reports Completion of Patient Enrollment in P-II CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

 NGM Reports Completion of Patient Enrollment in P-II CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

NGM Reports Completion of Patient Enrollment in P-II CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Shots:

  • The company has completed enrollment in the P-II CATALINA study evaluating the safety and efficacy of NGM621 (IVT injections, q4w/ q8w) vs sham control in 320 patients with geographic atrophy secondary to AMD. The results are expected in H2’22
  • The 1EPs of the P-II CATALINA study is the rate of change in geographic atrophy lesion area as measured by FAF imaging @52 wks. of treatment & will evaluate the incidence and severity of ocular and systemic AEs
  • Additionally, the P-I results demonstrate that the therapy was well-tolerated and had an acceptable safety profile. NGM621 is a mAb engineered to inhibit complement C3

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: NGM Biopharmaceuticals

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post